Abstract 12446: Impact of Soluble LR11 on Target Lesion Revascularization After Coronary Intervention in Patients with Stable Coronary Artery Disease
Background: LR11, an LDL receptor family member, is a novel marker of intimal smooth muscle cells (SMC). The circulating LR11 likely reflect the pathophysiological condition of intimal SMCs, and is a novel marker of intimal SMCs proliferation. However, it has remained uncertain that LR11 predict restenosis after coronary intervention as a results of proliferation of SMC. We evaluated LR11 as a predicitor of target lesion revascularization (TLR) after coronary stenting in patients with coronary artery disease (CAD).
Methods: Two hundred nine consecutive SAP patients (mean age 67.0±9.4 years, male 81.8%) treated with PCI who had follow-up coronary angiography were enrolled in this study. Clinical and angiographic data including serum sLR11 were obtained at baseline and follow-up (mean follow-up period 235±48 days). The DES use was 82% of all subjects. Overall, serum sLR11 at follow-up was significantly lower in TLR patients than that in TLR subjects (8.10±2.31 vs 9.35±3.30, p=0.047) though there was no significant difference at baseline characteristics.Multivariate logistic regression analyses were performed to identify the clinical and angiographic predictors of TLR. Percent change in sLR11 (10% change, odds ratio (OR) 1.28, 95% confidence interval (CI) 1.01–1.63, p=0.043) was a significant predictor of TLR.
Conclusion: Our results demonstrated that sLR11 might have an impact on the TLR in patients with stable CAD following coronary intervention. Futher study needed to elucidate the mechanism of how sLR11 plays a role in local reaction after coronary stenting
- © 2010 by American Heart Association, Inc.